First of Its Kind SARS-CoV-2 Antibody Test Enables Personalized COVID-19 Assessments

Now, a new test using best-in-class technology offers each patient a personalized status of his or her protection against COVID-19, making it an important new tool in the enduring fight against the pandemic.

The PictArray SARS-CoV-2 assay from Pictor Limited (Auckland, New Zealand) is a first of its kind test will enable high efficacy personalized COVID-19 assessments by detecting if a patient has antibodies from a previous infection of SARS-CoV-2 (from spike protein (SP) and nucleocapsid protein (NP) antibodies) or from vaccination alone (SP antibodies only). The assay which is based on Pictor’s PictArray multiplexed technology will also indicate whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).

PictArray multiplexed technology makes it possible to test multiple disease markers in a single test simultaneously - with higher sensitivity, faster throughput, and reduced turn-around time. The PictArray SARS-CoV-2 IgG ELISA Kit enables more informed clinical intervention to manage the threat of COVID-19. Due to its ability to differentiate between natural and vaccine-based antibodies, the PictArray test is an advancement with critical applications, including vaccine development.

“The PictArray SARS-CoV-2 Antibody Test is a high performance, all-in-one, NP/SP COVID-19 antibody test with serological differentiation. This is the only known test that separately measures antibodies from vaccines and SARS-CoV-2 infection in one test,” explained Pictor’s Chief Medical Officer Tadd Lazarus, MD. “The separate detection of SP and NP enables more precise clinical intervention.”

Related Links:
Pictor Limited